Payment overview · 2025
General Payments
$1,227.66
33 reported records · 10 companies
Healthcare provider profile · identity verified
Rita Shah, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BERKLEY, MI · NPI 1639156441
Verified facts
What the public records show
CMS Open Payments records show Rita Shah, MD received $1,227.66 in general payments during 2025 across 33 reported records.
Medtronic, Inc. accounted for 44.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$549.84 | 44.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $465.20 | 37.9% | 22 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.28 | 3.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $43.48 | 3.5% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $25.40 | 2.1% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $23.62 | 1.9% | 1 | 2025 |
| Amphastar Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.93 | 1.9% | 1 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $21.85 | 1.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.29 | 1.4% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $13.77 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $677.82 | 32 |
| Travel and Lodging | $549.84 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $549.84 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $307.02 | 14 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $66.01 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $49.79 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $44.28 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $43.48 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $25.40 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $23.62 | 1 | 2025 |
Source payment records
|
|||||
| SEROQUEL Normalized: seroquel |
Drug | AstraZeneca Pharmaceuticals LP | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $21.85 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $17.29 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $13.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 63 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 72 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
63 | 20 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
72 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 302 | 97 |
| Amlodipine Besylate | Amlodipine Besylate | 224 | 71 |
| Levothyroxine Sodium | Levothyroxine Sodium | 214 | 72 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 160 | 57 |
| Simvastatin | Simvastatin | 148 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 128 | 43 |
| Metformin Hcl | Metformin Hcl | 126 | 44 |
| Losartan Potassium | Losartan Potassium | 123 | 30 |
| Ozempic | Semaglutide | 101 | 18 |
| Alprazolam | Alprazolam | 97 | 23 |
| Atenolol | Atenolol | 96 | 35 |
| Montelukast Sodium | Montelukast Sodium | 96 | 33 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 93 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 92 | 29 |
| Lisinopril | Lisinopril | 86 | 26 |
| Omeprazole | Omeprazole | 82 | 25 |
| Allopurinol | Allopurinol | 81 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 81 | 15 |
| Carvedilol | Carvedilol | 76 | 30 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 75 | 26 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 73 | 23 |
| Jardiance | Empagliflozin | 72 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 64 | 15 |
| Farxiga | Dapagliflozin Propanediol | 63 | 20 |
| Furosemide | Furosemide | 62 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 59 | 24 |
| Valsartan | Valsartan | 58 | 22 |
| Eliquis | Apixaban | 54 | 12 |
| Metformin Hcl Er | Metformin Hcl | 53 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 51 | 15 |
| Trazodone Hcl | Trazodone Hcl | 51 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 18 |
| Potassium Chloride | Potassium Chloride | 45 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 42 | 20 |
| Rybelsus | Semaglutide | 41 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 39 | 13 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 38 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | 12 |
| Tramadol Hcl | Tramadol Hcl | 30 | suppressed |
| Gabapentin | Gabapentin | 29 | suppressed |
| Glimepiride | Glimepiride | 28 | suppressed |
| Nifedipine Er | Nifedipine | 28 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 28 | 11 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 27 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 26 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 25 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 20 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 18 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Famotidine | Famotidine | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 15 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,227.66 · 33 records | Medtronic, Inc. | AIRSUPRA, BREZTRI, Cologuard Collection Kit, FARXIGA, GVOKE HYPOPEN, JARDIANCE, JATENZO, Kerendia, Korlym, MINIMED 780G, SEROQUEL, t:slim X2 Insulin Pump with Control-IQ | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error